Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease (PD), a progressive neurodegenerative disorder, is associated with the destruction of dopamine neurons in the substantia nigra (SN) and the formation of Lewy bodies in basal ganglia. Risk factors for PD include aging, as well as environmental and genetic factors. Recent converging reports suggest a role for the gut microbiome and epigenetic factors in the onset and/or progression of PD. Of particular relevance and potential therapeutic targets in this regard are histone deacetylases (HDACs), enzymes that are involved in chromatin remodeling. Butyrate, a short-chain fatty acid (FA) produced in the gut and presumably acting via several G protein-coupled receptors (GPCRs) including FA3 receptors (FA3Rs), is a well-known HDAC inhibitor that plays an important role in maintaining homeostasis of the gut-brain axis. Recently, its significance in regulation of some critical brain functions and usefulness in neurodegenerative diseases such as PD has been suggested. In this study we sought to determine whether butyrate may have protective effects against salsolionl (SALS)-induced toxicity in SH-SY5Y cells. SALS, an endogenous product of aldehyde and dopamine condensation, may be selectively toxic to dopaminergic neurons. SH-SY5Y cells, derived from human neuroblastoma cells, are used as a model of these neurons. Exposure of SH-SY5Y cells for 24 h to 400 μM SALS resulted in approximately 60% cell death, which was concentration-dependently prevented by butyrate. The effects of butyrate in turn were significantly attenuated by beta-hydroxy butyrate (BHB), a selective FA3R antagonist. Moreover, a selective FA3R agonist (AR 420626) also provided protective effects against SALS, which was totally blocked by BHB. These findings provide further support that butyrate or an agonist of FA3R may be of therapeutic potential in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
The SH-SY5Y cell line in Parkinson’s disease research: a systematic review
Xicoy, H., Wieringa, B., & Martens, G. J. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0149-0 · Cited by 1,036
Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology
Kovalevich, J., & Langford, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-640-5_2 · Cited by 1,005
Microbiome–microglia connections via the gut–brain axis
Abdel-Haq, R., Schlachetzki, J. C. M., Glass, C. K., & Mazmanian, S. K. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180794 · Cited by 471
Zhou, D., Pan, Q., Shen, F., Cao, H.-X., Ding, W.-J., Chen, Y.-W., & Fan, J.-G. (2017) · Scientific Reports · doi:10.1038/s41598-017-01751-y · Cited by 421
The Pharmacology and Function of Receptors for Short-Chain Fatty Acids
Bolognini, D., Tobin, A. B., Milligan, G., & Hodge, D. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.102301 · Cited by 267
Microglia in Parkinson's disease
Ho, M. S. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-9913-8_13 · Cited by 227
Liu, J., Wang, F., Liu, S., Du, J., Hu, X., Xiong, J., Fang, R., Chen, W., & Sun, J. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3235 · Cited by 218
Butyrate, a metabolite of intestinal bacteria, enhances sleep
Szentirmai, É., Millican, N. S., Massie, A. R., & Kapás, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-43502-1 · Cited by 216
Cited by
The gut microbiome as a modulator of healthy ageing
Ghosh, T. S., Shanahan, F., & O’Toole, P. W. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00605-x · Cited by 817
Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
Hamamah, S., Aghazarian, A., Nazaryan, A., Hajnal, A., & Covasa, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020436 · Cited by 307
Role of histone deacetylases and their inhibitors in neurological diseases
Zhang, L.-Y., Zhang, S.-Y., Wen, R., Zhang, T.-N., & Yang, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107410 · Cited by 84
Chan, D. G., Ventura, K., Villeneuve, A., Du Bois, P., & Holahan, M. R. (2022) · Journal of Parkinson's Disease · doi:10.3233/jpd-223461 · Cited by 24
“Specifically, butyrate can act as a histone deacetylase and bind onto G protein-coupled receptors, FA3 receptors, and prevent dopaminergic cell death and lead to increased striatal dopamine levels [92, 93].”
Background
Metadata
- Authors
- Getachew, B., Csoka, A. B., Bhatti, A., Copeland, R. L., & Tizabi, Y.
- Venue
- Neurotoxicity Research
- Published
- 2020-06-22
- Volume
- 38
- Issue
- 3
- Pages
- 596-602
- ISSN
- 1029-8428 (ISSN-L)
- 1476-3524
- OpenAlex
- W3036488918
- Cited by
- 51
- References
- 16
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson’s Disease. https://app.cochat.ai/papers/10.1007/s12640-020-00238-5
- The paper
- Getachew, B., Csoka, A. B., Bhatti, A., Copeland, R. L., & Tizabi, Y. (2020). Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson’s Disease. Neurotoxicity Research. https://doi.org/10.1007/s12640-020-00238-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.